Alt-R™ Genome Editing Detection Kit T7 endonuclease I (T7EI) mismatch cleavage assay for detection of on-target editing, known off-target events, and estimation of genome editing efficiency in cultured cells. Learn more Explore resources ...
除了提高CRISPR-Cas编辑系统的特异性,开发普适、高敏、无偏倚并且能够体内监测脱靶效应的方法也是CRISPR技术走向临床过程中必须关注的一环。 2019年4月19,Science杂志同期正式发表了基因编辑领域3篇Report,其中两篇正是上文3月1日在线发表的文章,而另...
DISCOVER-seq (discovery of in situ Cas off-targets and verification by sequencing) is a broadly applicable approach for unbiased CRISPR–Cas off-target identification in cells and tissues. It leverages the recruitment of DNA repair factors to double-strand breaks (DSBs) after genome editing with ...
2.Chuai, G., et al., DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol, 2018. 19(1): p. 80. 3.Jifang Y., et al., Benchmarking and integrating genome-wide CRISPR off-target detection and prediction.NAR, 2020. gkaa930,https://doi.org/10.1093/nar/gkaa93...
Genomics: CRISPR off-target detectionCRISPRSBIOLOGICAL tagsGENOME editingWang , X. et al . Nat.doi:10.1038/nmeth.3301NoneNature Methods
Identification of off-target editing activity, including the type, frequency, and location of all off-target editing events. 由于目前大部分CRISPR基因编辑治疗方案是基于CRISPR引起的DNA双链断裂和随机突变进行基因敲除,所以第一类风险主要是指靶位点的随机突变引发的安全风险,如果出现大片段丢失、染色体重排等异常...
Moreover, we demonstrate that PEAC-seq could identify DNA translocations, which are more genotoxic but usually overlooked by other off-target detection methods. As PEAC-seq does not rely on exogenous oligodeoxynucleotides to label the editing site, we also conduct in vivo off-target identification ...
相关研究结果发表在2019年4月19日的Science期刊上,论文标题为“Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq”。论文通讯作者为加州大学伯克利分校的Jacob E. Corn。论文第一作者为加州大学伯克利分校的Beeke Wienert和Stacia Wyman。
In summary, DISCOVER-Seq is a valuable tool forin vivodetection of off-target guide activity. Based on its performance, the authors are hopeful for its real-time use in therapeutics in the future. They are working on improving several aspects of it to move forward in this direction. “I ...
Since the CRISPR genome editing technology was invented in 2012, it has shown great promise to treat a number of intractable diseases. However, scientists have struggled to identify potential off-target effects in therapeutically relevant cell types, whi